Track record · closed signal

Pfizer Inc. (PFE) — closed signal from December 29, 2025

Near target Published before the outcome was known, scored automatically when the window closed on March 29, 2026 — +7.6% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$24.80 – $25.30Entry zone — fair-value band

$25.12Published — price the day we called it

$28.13Target — the price the thesis aimed for

$27.94Peak — highest point inside the window, not a realized return

$27.04Window close — end-of-window price, context only

What happened

Near target

Came within reach: 93% of the predicted growth at its peak, just short of the target.

At window close

+7.6%

realized, from the publication price to the last close inside the window

Peak gain

+11.2%

peak, from the publication price — not a realized return

S&P 500, same window

-7.6%

SPY over the identical days, dividend-adjusted

Window close

$27.04

last close inside the window, ended March 29, 2026

Peak price

$27.94

peak on February 11, 2026 — not a realized return

Days to target

—

The thesis — published December 29, 2025

Predicted growth

+12%

over the measurement window

Target price

$28.13

the price the thesis aimed for

Entry zone

$24.80 – $25.30

the fair-value band we waited for

Price at publication

$25.12

published December 29, 2025

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer looks like a short-term trade for income and quick recovery rather than a long-term buy. The stock pays a high dividend near 6.8% which attracts buyers, but the company is currently paying out more than it earns, so the dividend may not last. After heavy recent selling, a bounce is possible, but headlines can cause sudden drops. Treat this as a tactical rebound with strict risk limits.

Primary drivers

Been sold a lot recently, so a short-term rebound is possible
Investors move to healthcare in sell-offs, which can lift demand
High dividend attracts buyers, but payout may not be sustainable
News about obesity/metabolic drugs keeps the sector in focus

How it played out

PFE: target missed after an 11.2% peak gain

Lyra published PFE on 2025-12-29 at $25.12 as a short-term rebound trade. The thesis expected 12% growth and pointed to recent selling, possible healthcare demand during sell-offs, a high dividend near 6.8%, and obesity and metabolic drug news keeping the sector in focus. It also treated the setup as tactical, with headline risk.

Inside the window from 2025-12-29 to 2026-03-29, PFE rose to a peak of $27.94 on 2026-02-11. That was an 11.2% gain, but it stayed below the $28.13 target. It ended at $27.04. The thesis mostly played out, but the target was not reached.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals